|
gptkbp:instanceOf
|
gptkb:drug
|
|
gptkbp:approvedBy
|
1991
|
|
gptkbp:ATCCode
|
gptkb:J01FA09
|
|
gptkbp:availableOn
|
many countries worldwide
|
|
gptkbp:brand
|
gptkb:clarithromycin
|
|
gptkbp:contraindication
|
hypersensitivity to macrolides
severe liver dysfunction
|
|
gptkbp:drugClass
|
macrolide
|
|
gptkbp:excretion
|
gptkb:kidney
|
|
gptkbp:form
|
gptkb:tablet
oral suspension
extended-release tablet
|
|
gptkbp:halfLife
|
3-7 hours
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Klaricid
|
|
gptkbp:indication
|
skin infections
respiratory tract infections
Helicobacter pylori eradication
|
|
gptkbp:interactsWith
|
gptkb:warfarin
gptkb:carbamazepine
gptkb:digoxin
statins
colchicine
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:manufacturer
|
gptkb:Abbott_Laboratories
|
|
gptkbp:mechanismOfAction
|
inhibits bacterial protein synthesis
|
|
gptkbp:metabolism
|
liver
|
|
gptkbp:pregnancyCategory
|
C (US)
|
|
gptkbp:routeOfAdministration
|
oral
intravenous
|
|
gptkbp:sideEffect
|
nausea
diarrhea
abdominal pain
taste disturbance
|
|
gptkbp:usedFor
|
bacterial infections
|
|
gptkbp:bfsParent
|
gptkb:clarithromycin
|
|
gptkbp:bfsLayer
|
6
|